X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs PIRAMAL ENTERPRISES - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS PIRAMAL ENTERPRISES NOVARTIS/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 351.0 38.2 917.7% View Chart
P/BV x 17.3 3.8 453.5% View Chart
Dividend Yield % 1.7 0.6 261.8%  

Financials

 NOVARTIS   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    NOVARTIS
Mar-16
PIRAMAL ENTERPRISES
Mar-16
NOVARTIS/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs9821,065 92.2%   
Low Rs556805 69.1%   
Sales per share (Unadj.) Rs252.9383.0 66.0%  
Earnings per share (Unadj.) Rs62.155.1 112.8%  
Cash flow per share (Unadj.) Rs63.374.1 85.5%  
Dividends per share (Unadj.) Rs10.0017.50 57.1%  
Dividend yield (eoy) %1.31.9 69.5%  
Book value per share (Unadj.) Rs363.6719.9 50.5%  
Shares outstanding (eoy) m31.96172.56 18.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.02.4 124.6%   
Avg P/E ratio x12.417.0 72.9%  
P/CF ratio (eoy) x12.212.6 96.3%  
Price / Book Value ratio x2.11.3 162.8%  
Dividend payout %16.131.8 50.7%   
Avg Mkt Cap Rs m24,580161,344 15.2%   
No. of employees `0000.83.8 19.9%   
Total wages/salary Rs m1,80116,898 10.7%   
Avg. sales/employee Rs Th10,748.917,472.6 61.5%   
Avg. wages/employee Rs Th2,395.24,466.9 53.6%   
Avg. net profit/employee Rs Th2,641.12,512.8 105.1%   
INCOME DATA
Net Sales Rs m8,08366,099 12.2%  
Other income Rs m8292,425 34.2%   
Total revenues Rs m8,91368,524 13.0%   
Gross profit Rs m23418,723 1.3%  
Depreciation Rs m373,274 1.1%   
Interest Rs m29,388 0.0%   
Profit before tax Rs m1,0258,485 12.1%   
Minority Interest Rs m03 0.0%   
Prior Period Items Rs m171,593 1.0%   
Extraordinary Inc (Exp) Rs m1,696457 371.4%   
Tax Rs m7521,032 72.9%   
Profit after tax Rs m1,9869,506 20.9%  
Gross profit margin %2.928.3 10.2%  
Effective tax rate %73.412.2 603.2%   
Net profit margin %24.614.4 170.8%  
BALANCE SHEET DATA
Current assets Rs m12,67847,488 26.7%   
Current liabilities Rs m2,433104,362 2.3%   
Net working cap to sales %126.7-86.0 -147.3%  
Current ratio x5.20.5 1,145.1%  
Inventory Days Days3341 80.5%  
Debtors Days Days2251 44.0%  
Net fixed assets Rs m6926,532 0.3%   
Share capital Rs m160345 46.3%   
"Free" reserves Rs m11,460114,024 10.1%   
Net worth Rs m11,621124,221 9.4%   
Long term debt Rs m075,812 0.0%   
Total assets Rs m14,400308,356 4.7%  
Interest coverage x570.51.9 29,965.6%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.60.2 261.9%   
Return on assets %13.86.1 225.3%  
Return on equity %17.17.7 223.3%  
Return on capital %23.610.0 236.7%  
Exports to sales %0.717.2 4.3%   
Imports to sales %18.66.6 281.6%   
Exports (fob) Rs m6011,362 0.5%   
Imports (cif) Rs m1,5034,364 34.4%   
Fx inflow Rs m18614,435 1.3%   
Fx outflow Rs m1,8215,183 35.1%   
Net fx Rs m-1,6359,253 -17.7%   
CASH FLOW
From Operations Rs m2,531-67,773 -3.7%  
From Investments Rs m-8,270-8,768 94.3%  
From Financial Activity Rs m-38676,199 -0.5%  
Net Cashflow Rs m-6,125-342 1,788.7%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 4.0 50.0%  
FIIs % 1.6 26.6 6.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 16.5 130.3%  
Shareholders   41,647 93,274 44.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare NOVARTIS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Pharma Drug Approvals, Global Updates, Oil Prices, and Top Stocks in Action Today(Pre-Open)

Indian share markets snapped their losing streak seen during last week and closed their Wednesday session on a positive note.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 16, 2017 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS